Does Abbvie Own Allergan and the Implications for the Industry

Abbvie's acquisition of Allergan was a significant event in the pharmaceutical industry. In 2020, Abbvie announced its intention to acquire Allergan in a deal worth around $63 billion. The acquisition was completed in December 2020.

The acquisition of Allergan by Abbvie has had far-reaching implications for the industry. Abbvie's purchase of Allergan's assets has given the company a significant boost in its dermatology and aesthetics portfolio.

One of the key assets Abbvie gained from the acquisition is Allergan's Botox business. Botox is a highly successful product that has been used for decades to treat a range of conditions, including facial wrinkles and migraines.

Expand your knowledge: Allergan Ticker Symbol

AbbVie has completed its $63 billion acquisition of Allergan plc.

AbbVie will add established brands to its small and mature CNS franchise, including Depakote and Luvox.

The acquisition will also give AbbVie a strong foothold in the ophthalmology space.

Allergan has a range of late-phase assets with moderate revenue potential in the near- and mid-term, helping to offset the loss of Humira revenue.

Recommended read: Abbvie Allergan Acquisition

The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets.

AbbVie's presence in ophthalmology is minor, but Allergan is well established in this area with multiple current and late-stage therapies.

The move significantly expands and diversifies AbbVie's revenue base, complementing existing leadership positions in immunology and haematologic oncology.

AbbVie's diversified on-market portfolio will drive existing growth to approximately $30 billion in revenues in full year 2020, with combined revenues of approximately $50 billion.

Allergan's psychiatry, migraine, and ophthalmology assets will infuse revenue into AbbVie's bottom line in the near-to-mid-term, if AbbVie can successfully commercialize Allergan's late-phase pipeline products.

The future of AbbVie's ophthalmology portfolio will hinge on the success of key emerging therapies, including abicipar pegol in wet AMD and bimatoprost SR in glaucoma.

Discover more: Can I Make an Existing Bank Account Joint

AbbVie's presence in ophthalmology is minor, with only Humira approved for non-infectious uveitis of the posterior segment.

Allergan, on the other hand, is well established in ophthalmology with multiple current and late-stage therapies.

These therapies could provide a stable revenue stream for AbbVie in the near-term.

AbbVie has no pipeline assets in ophthalmology, making the acquisition of Allergan a significant addition to its business.

The ophthalmology space is a new area of focus for AbbVie, but one that has the potential for significant growth.